AUGMENTATION OF LYMPHOKINE-ACTIVATED KILLER-CELL ACTIVITY BY LENTINAN

被引:2
作者
TANI, M
TANIMURA, H
YAMAUE, H
TSUNODA, T
IWAHASHI, M
NOGUCHI, K
TAMAI, M
HOTTA, T
MIZOBATA, S
机构
关键词
LENTINAN; LAK; AUTOLOGOUS TUMOR KILLING ACTIVITY; INTERLEUKIN; 2; IL-2; RECEPTOR;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Lymphokine - activated killer (LAK) activity stimulated by interleukin 2 (IL - 2) and/or lentinan was examined in the peripheral blood of 9 healthy subjects and 7 cancer patients. After 4 and 8 days culture, LAK killer activity stimulated by IL - 2 and lentinan against autologous turner and K562 cells was gr eater than that stimulated by IL - 2 alone. The optimal concentration of lentinan for the generation of killer cells ranged from 25 - 500 ng/ml, a level which can be achieved in vivo by the administration of clinical doses of this agent. The expression of CD25 antigen, the a chain of the IL - 2 receptor on the activated killer cells was increased by lentinan. Thus it was shown that LAK cells stimulated with IL - 2 plus lentinan had strong cytotoxicity and might be useful as effector cells for adoptive immunotherapy.
引用
收藏
页码:1773 / 1776
页数:4
相关论文
共 19 条
[1]
INDUCTION OF AUTOLOGOUS TUMOR-SPECIFIC CYTOTOXIC T-CELLS IN PATIENTS WITH LIVER-CANCER - CHARACTERIZATIONS AND CLINICAL UTILIZATION [J].
ARUGA, A ;
YAMAUCHI, K ;
TAKASAKI, K ;
FURUKAWA, T ;
HANYU, F .
INTERNATIONAL JOURNAL OF CANCER, 1991, 49 (01) :19-24
[2]
CHIHARA G, 1969, NATURE, V222, P637
[3]
FACHET J, 1980, INT J CANCER, V25, P371
[4]
FLETCHER M, 1987, LYMPHOKINE RES, V6, P45
[5]
MOLECULAR CHARACTERIZATION OF INTERLEUKIN-2 [J].
GILLIS, S ;
MOCHIZUKI, DY ;
CONLON, PJ ;
HEFENEIDER, SH ;
RAMTHUN, CA ;
GILLIS, AE ;
FRANK, MB ;
HENNEY, CS ;
WATSON, JD .
IMMUNOLOGICAL REVIEWS, 1982, 63 :167-209
[6]
Hamuro J, 1984, IMMUNE MODULATION AG, P409
[7]
LOTZE MT, 1985, J IMMUNOL, V135, P2865
[8]
OBSERVATIONS ON THE SYSTEMIC ADMINISTRATION OF AUTOLOGOUS LYMPHOKINE-ACTIVATED KILLER CELLS AND RECOMBINANT INTERLEUKIN-2 TO PATIENTS WITH METASTATIC CANCER [J].
ROSENBERG, SA ;
LOTZE, MT ;
MUUL, LM ;
LEITMAN, S ;
CHANG, AE ;
ETTINGHAUSEN, SE ;
MATORY, YL ;
SKIBBER, JM ;
SHILONI, E ;
VETTO, JT ;
SEIPP, CA ;
SIMPSON, C ;
REICHERT, CM .
NEW ENGLAND JOURNAL OF MEDICINE, 1985, 313 (23) :1485-1492
[9]
EXPERIENCE WITH THE USE OF HIGH-DOSE INTERLEUKIN-2 IN THE TREATMENT OF 652 CANCER-PATIENTS [J].
ROSENBERG, SA ;
LOTZE, MT ;
YANG, JC ;
AEBERSOLD, PM ;
LINEHAN, WM ;
SEIPP, CA ;
WHITE, DE .
ANNALS OF SURGERY, 1989, 210 (04) :474-485
[10]
A NEW APPROACH TO THE ADOPTIVE IMMUNOTHERAPY OF CANCER WITH TUMOR-INFILTRATING LYMPHOCYTES [J].
ROSENBERG, SA ;
SPIESS, P ;
LAFRENIERE, R .
SCIENCE, 1986, 233 (4770) :1318-1321